Literature DB >> 12815543

Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea.

Banmeet Anand1, Yasser Nashed, Ashim Mitra.   

Abstract

PURPOSE: A series of dipeptide prodrugs of antiviral nucleoside acyclovir (ACV) were designed to target the oligopeptide transporter on the cornea with an aim of improving the ocular bioavailability and therapeutic activity of ACV.
METHODS: Aqueous stability, ocular bioreversion kinetics in various tissues, in vitro antiviral activity, cell proliferation assay and corneal transport characteristics of the dipeptide prodrugs were studied. Results. ACV dipeptide prodrugs were found to be more stable at pH 5.6 in comparison to L-Val-ACV, an amino acid prodrug of ACV. The prodrugs exhibited higher solubility than ACV. Val-Val-ACV and Val-Tyr-ACV were found to have excellent antiviral activity against herpes simplex virus-1 (HSV-1). All the dipeptide prodrugs exhibited lower cytotoxicity as compared to currently approved anti-HSV agent, trifluorothymidine (TFT). Transport of [(3)H] Val-ACV was inhibited significantly in the presence of the dipeptide prodrugs of ACV. Corneal permeabilities of all the ACV dipeptide prodrugs were observed to be higher than ACV possibly due to recognition of the prodrugs by the oligopeptide transporter on the cornea.
CONCLUSIONS: The dipeptide prodrugs were found to be more permeable than the parent drug, ACV. More permeable, less cytotoxic ACV dipeptide prodrugs exhibited excellent chemical stability and antiviral activity against herpes simplex virus thereby rendering these lead compounds promising drug candidates against herpes virus infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815543     DOI: 10.1076/ceyr.26.3.151.14893

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  19 in total

1.  Disposition kinetics of a dipeptide ester prodrug of acyclovir and its metabolites following intravenous and oral administrations in rat.

Authors:  Ravi S Talluri; Ripal Gaudana; Sudharshan Hariharan; Ritesh Jain; Ashim K Mitra
Journal:  Clin Res Regul Aff       Date:  2009-01-01

Review 2.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 3.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

Review 4.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

Review 5.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

Review 6.  Drug and gene delivery to the back of the eye: from bench to bedside.

Authors:  Cheryl L Rowe-Rendleman; Shelley A Durazo; Uday B Kompella; Kay D Rittenhouse; Adriana Di Polo; Alan L Weiner; Hans E Grossniklaus; Muna I Naash; Alfred S Lewin; Alan Horsager; Henry F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-28       Impact factor: 4.799

7.  Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.

Authors:  Jwala Jwala; Sai H S Boddu; Sujay Shah; Suman Sirimulla; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-04       Impact factor: 2.671

8.  Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity.

Authors:  Uttio Roy Chowdhury; Kimberly B Viker; Kristen L Stoltz; Bradley H Holman; Michael P Fautsch; Peter I Dosa
Journal:  J Med Chem       Date:  2016-07-01       Impact factor: 7.446

9.  Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir.

Authors:  Ravi S Talluri; Swapan K Samanta; Ripal Gaudana; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-06-23       Impact factor: 5.875

10.  Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement.

Authors:  Soumyajit Majumdar; Tushar Hingorani; Ramesh Srirangam; Rama Sarma Gadepalli; John M Rimoldi; Michael A Repka
Journal:  Pharm Res       Date:  2008-10-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.